This page provides a curated selection of reputable, peer-reviewed and institutional resources on cannabis and cannabinoids for healthcare professionals and pharmacies. It is intended for education only and does not replace clinical judgement, local guidelines, or regulatory advice.
Full citation:
National Academies of Sciences, Engineering, and Medicine.
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017.
Type: Comprehensive evidence review (10,000+ studies)
Abstract (summary for clinicians):
This landmark report synthesises thousands of studies evaluating the health effects of cannabis
and cannabinoids. It concludes that there is substantial evidence to support use of cannabis-based
products for several indications (such as certain pain and spasticity contexts), moderate evidence
for others, and limited or insufficient evidence in many areas where cannabis is commonly used in
practice. The authors also review potential adverse effects and public health considerations, and
call for improved research quality. Overall, the report positions cannabis and cannabinoids as
clinically relevant but complex therapeutic options that should be considered within regulated,
prescriber-supervised frameworks.
Key clinical takeaways:
Source: Harvard Health Publishing – “Medical marijuana” (topic overview, updated periodically)
Type: Clinical overview for health professionals and patients
Summary:
Harvard Health provides a balanced overview of medical marijuana, including potential therapeutic
applications, routes of administration, adverse effects, and regulatory considerations in
jurisdictions where it is permitted. The piece acknowledges that cannabis-based therapies can be
useful for selected patients under supervision, while emphasising the importance of evidence-based
prescribing and awareness of potential harms.
Key clinical takeaways:
Example citation:
The Lancet Psychiatry. Various articles on cannabis, mental health, and therapeutic opportunities and risks.
Type: Peer-reviewed commentary and reviews
Summary:
Articles in The Lancet Psychiatry discuss both potential therapeutic applications of
cannabinoids and the mental health risks associated with heavy or early-onset use, particularly
in vulnerable populations. While cautious about psychiatric harms, the journal recognises that
cannabinoids may have roles in specific indications when used within controlled clinical settings.
Key clinical takeaways:
Example link:
https://www.thelancet.com/journals/lanpsy
Example citation:
NEJM Perspective articles on cannabinoids and their evolving role in medicine.
Type: Perspective / clinical commentary
Summary:
NEJM perspectives describe the growing integration of cannabinoid-based medicines into
contemporary clinical practice, particularly in areas such as epilepsy and symptom management
where evidence is more established. The articles highlight the need for standardised formulations,
pharmacovigilance, and alignment with regulatory frameworks, while acknowledging that cannabinoids
now occupy a legitimate, if evolving, place in modern therapeutics.
Key clinical takeaways:
Link (example):
https://www.nejm.org/
Source: BMJ editorial content on cannabis-based medicines
Type: Editorial / opinion in a high-impact medical journal
Summary:
BMJ editorials argue that cannabis-based medicines should not be overlooked as potential
therapeutic tools when supported by evidence and used in regulated pathways. They support
structured access, prescriber oversight, and clear product standards, while cautioning against
both uncritical enthusiasm and excessive regulatory barriers that limit access for appropriate patients.
Key clinical takeaways:
Link (example):
https://www.bmj.com/
Source: UCLA Semel Institute – Cannabis Research Initiative
Type: Academic research program overview
Summary:
The UCLA Cannabis Research Initiative outlines key areas of scientific investigation, including
therapeutic potential, public health implications, and policy impacts of cannabis use. The
initiative reflects growing recognition within academic medicine that cannabis is a significant
area of clinical and translational research, with potential benefits when used appropriately and
clear risks when misused.
Key clinical takeaways:
Source: The Conversation – “What we know about medicinal cannabis so far”
Type: Expert-written explainer (Australia-specific)
Summary:
This article summarises the current evidence for medicinal cannabis use in Australia, reviewing
indications where data are strongest, the regulatory framework, and practical considerations for
prescribers. It presents medicinal cannabis as an emerging therapeutic option within Australia’s
tightly regulated system, emphasising clinician oversight, patient selection, and the need for
ongoing research.
Key clinical takeaways:
Link:
https://theconversation.com/what-we-know-about-medicinal-cannabis-so-far-2017
Source: Parliament of Australia – Parliamentary Library
Type: Policy and regulatory overview
Summary:
This guide outlines the legislative and regulatory framework for medicinal cannabis in Australia,
including federal reforms, access schemes, and scheduling. It recognises the therapeutic use of
cannabis-based products under specific conditions and provides context for how these therapies fit
within Australia’s broader medicines and controlled substances system.
Key clinical takeaways:
Link:
https://www.aph.gov.au/
Disclaimer: This evidence library is for informational purposes only and is restricted to healthcare professionals and pharmacies. It is not intended as medical advice for the public and does not endorse any specific product or brand. Prescribing decisions should be based on the totality of evidence, individual patient circumstances, and applicable regulatory requirements.
